Best Grants for Cancer Nonprofits in Northern Mariana Islands

Cancer research institutions and translational research centers in the Northern Mariana Islands and other U.S. territories can seek funding to advance prevention, early detection, diagnosis, and treatment of organ-specific or closely related cancers. National Institutes of Health SPORE P50 center grants provide US $25,000,000 for state-of-the-art, human biology-based translational cancer research with clear clinical endpoints.

Cancer research institutions and medical researchers in the Northern Mariana Islands can apply for up to US $2,500,000 to study how bariatric surgery affects cancer risk. Focused on cancer and obesity mechanisms, the National Institutes of Health supports investigator-initiated projects through the National Cancer Institute with multiple standard and renewal deadlines through 2027.

The R01 grant program aims to address disparities in liver diseases and liver cancer in the United States. It supports multi-level intervention research targeting populations with significant health disparities. With deadlines spanning from February 2024 to June 2027, this initiative encourages innovative approaches to improve health outcomes in underserved communities, ultimately enhancing public health and reducing inequities in healthcare access and treatment.

The National Human Genome Research Institute (NHGRI) is launching a Notice of Funding Opportunity (NOFO) aimed at enhancing genomic research through the development and distribution of high-value resources. This initiative encourages collaborative efforts in genomic resource development and the integration of data science in clinical applications. While applications are not currently being accepted, prospective applicants are urged to prepare meaningful collaborations and projects ahead of the formal solicitation.

The National Cancer Institute's PAIRS program aims to explore innovative cancer therapies by leveraging synthetic vulnerabilities that interact with tumor responses to radiation therapy. This initiative supports the development of targeted drug-radiation combinations, focusing on precision medicine to optimize treatment efficacy while minimizing harm to normal tissues. By consolidating prior funding opportunities, PAIRS encourages research that addresses context-dependent vulnerabilities, enhancing therapeutic strategies and aligning with NIH's scientific goals.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers by funding comprehensive, clinical, and basic cancer research. These grants facilitate the integration of diverse research capabilities, promoting innovative approaches to cancer prevention, diagnosis, and therapy. CCSGs encourage collaboration among researchers and the development of Shared Resources, ultimately enhancing the understanding of cancer and its treatment. This initiative supports the continuous discovery and dissemination of crucial research findings for community benefit.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

This funding opportunity aims to bolster the cancer surveillance workforce through educational initiatives. By enhancing collaborations with cancer partners and developing tools for improved data quality, this program will expand the capacity of registrars. Efforts will focus on recruitment and retention, ultimately ensuring compliance with Public Law 102-515. Strengthening the cancer registrar workforce will lead to timely and accurate cancer data submission, supporting public health objectives.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The National Cancer Institute (NCI) invites applications for innovative technologies aimed at cancer research and clinical care. This funding opportunity supports early-stage projects focused on proof-of-concept studies to assess the feasibility of new methods and tools. Applications should demonstrate significant technical innovation, targeting advancements in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology. Technologies may include novel analysis platforms, imaging technologies, and biospecimen processing innovations, with a focus on cancer applications.

Cancer research institutions and medical centers in the Northern Mariana Islands and other U.S. jurisdictions can seek funding to run clinical oncology career development programs that train clinician-scientists. US Dept. of Health & Human Services: National Institutes of Health supports K12 programs with multi-specialty oncology faculty, mentored research, and individualized career development in clinical and translational cancer research.

US Dept. of Health & Human Services: National Institutes of Health (NIH) provides Northern Mariana Islands cancer research institutions with Cancer Center Support Grants ranging from US $1,200,000 - US $1,500,000 for NCI-designated Cancer Centers. Funding supports center leadership, shared research resources, administration, planning, evaluation, and developmental projects advancing cancer prevention, diagnosis, treatment, and population science.

The National Cancer Institute (NCI) invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity allows for biphasic or monophasic applications to support both analytical and clinical validation phases. Successful projects will leverage human specimens to develop assays that enhance cancer treatment and prevention, ensuring multidisciplinary collaboration among scientists and clinicians. This initiative aims to improve cancer management through reliable and clinically validated tools.

Postdoctoral researchers conducting cancer-related clinical trials in the Northern Mariana Islands can access funding through grants from the National Institutes of Health to transition into independent, tenure-track or equivalent faculty roles. This award supports early-career investigators as they move from mentored positions to launching competitive, independent oncology research programs.

Research institutions and similar organizations conducting advanced pre-clinical work on nanotechnology-based cancer diagnostics or therapeutics in the Northern Mariana Islands can apply for NIH funding, with awards up to US $1,900,000. With a mission to advance cancer treatment, NIH supports projects maturing nanoparticle or nano-device interventions toward later-stage NCI translational programs.

Cancer and health-disparities research institutions in the Northern Mariana Islands can seek funding to develop multi-level interventions addressing disparities in liver diseases and liver cancer. US Dept. of Health & Human Services: National Institutes of Health supports projects serving U.S. populations experiencing health disparities through this R01 opportunity, with multiple standard and renewal deadlines through 2027.

Focused on cancer and oncology research careers, the National Institutes of Health invites clinical scientists to pursue mentored research development awards supporting biomedical, behavioral, and translational cancer studies. Eligible investigators from underrepresented backgrounds, including those based in the Northern Mariana Islands, receive protected time and training to advance toward independent cancer research funding.